Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss
Objectives/Hypothesis To examine the hearing outcomes of patients with sudden sensorineural hearing loss (SSNHL) treated with oral and intratympanic (IT) steroid only or a combination of steroid and migraine treatment. Our hypothesis was that adjuvant migraine medications may improve outcomes in SSN...
Gespeichert in:
| Veröffentlicht in: | The Laryngoscope 2021-01, Vol.131 (1), p.E283-E288 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E288 |
|---|---|
| container_issue | 1 |
| container_start_page | E283 |
| container_title | The Laryngoscope |
| container_volume | 131 |
| creator | Abouzari, Mehdi Goshtasbi, Khodayar Chua, Janice T. Tan, Donald Sarna, Brooke Saber, Tina Lin, Harrison W. Djalilian, Hamid R. |
| description | Objectives/Hypothesis
To examine the hearing outcomes of patients with sudden sensorineural hearing loss (SSNHL) treated with oral and intratympanic (IT) steroid only or a combination of steroid and migraine treatment. Our hypothesis was that adjuvant migraine medications may improve outcomes in SSNHL.
Methods
A retrospective chart review at a tertiary otology center was conducted to identify patients with SSNHL who received oral steroid and IT dexamethasone injection(s) with or without migraine medications (a combination of nortriptyline and topiramate).
Results
A total of 47 patients received oral steroid and IT dexamethasone injection(s) only, and 46 patients received oral steroid and IT dexamethasone injection(s) as well as migraine lifestyle changes plus a combination of nortriptyline and topiramate. There were no significant differences in demographics and baseline audiometric data between the two groups. Both groups demonstrated improvements in pure tone average (PTA) and hearing thresholds at 250 Hz and 8000 Hz posttreatment. However, compared to steroid‐only group, the adjuvant migraine medications group had significantly greater improvements in hearing thresholds at the lower frequencies (250 Hz, 500 Hz, 1000 Hz). Patients in the latter cohort also had greater improvement in PTA (P = .01) and received fewer IT injections (P = .04) PTA improvement of ≥ 10 dB was observed in 36 patients (78%) in the adjuvant migraine medications group and 22 patients (46%) in the control group (P < .001).
Conclusion
In multimodal treatment of SSNHL, supplementing oral and IT steroid with migraine medications may result in greater improvements in lower frequency hearing thresholds and PTA. Furthermore, adjuvant migraine treatment can lead to decrease in number of IT injections, thus reducing procedure‐related risks and complications.
Level of Evidence
3 Laryngoscope, 131:E283–E288, 2021 |
| doi_str_mv | 10.1002/lary.28618 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8011356</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2386287576</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4208-d89b54e0cfc27b394bc987d32c2bedd7081d646dc3fa4a4e5c280ef4338e1ec53</originalsourceid><addsrcrecordid>eNp9kVtLxDAQhYMoul5e_AGSRxGqubbpi7CIN1gRXAV9CmkyXSPdVpNW8d-bdVX0xacJzJczZ-YgtEvJISWEHTUmvB8ylVO1gkZUcpqJspSraJSaPFOS3W-gzRifCKEFl2QdbXDGBJdKjtB07J6GV9P2-MrPgvEt4Ctw3pred23EvsX9I-DbAKafQ6K6Gk8H56DFU2hjF9KHIZgGX4BJ7xmedDFuo7XaNBF2vuoWujs7vT25yCbX55cn40lmBSMqc6qspABia8uKipeisqUqHGeWVeBcQRR1ucid5bURRoC0TBGoBecKKFjJt9DxUvd5qObgbPKXrOjn4OfpIrozXv_ttP5Rz7pXrQilXOZJYP9LIHQvA8Rez3200DSmhW6ImnGVM1XIYoEeLFEb0oYB6p8xlOhFCnqRgv5MIcF7v439oN9nTwBdAm--gfd_pPRkfPOwFP0AGJ2U3g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2386287576</pqid></control><display><type>article</type><title>Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Abouzari, Mehdi ; Goshtasbi, Khodayar ; Chua, Janice T. ; Tan, Donald ; Sarna, Brooke ; Saber, Tina ; Lin, Harrison W. ; Djalilian, Hamid R.</creator><creatorcontrib>Abouzari, Mehdi ; Goshtasbi, Khodayar ; Chua, Janice T. ; Tan, Donald ; Sarna, Brooke ; Saber, Tina ; Lin, Harrison W. ; Djalilian, Hamid R.</creatorcontrib><description>Objectives/Hypothesis
To examine the hearing outcomes of patients with sudden sensorineural hearing loss (SSNHL) treated with oral and intratympanic (IT) steroid only or a combination of steroid and migraine treatment. Our hypothesis was that adjuvant migraine medications may improve outcomes in SSNHL.
Methods
A retrospective chart review at a tertiary otology center was conducted to identify patients with SSNHL who received oral steroid and IT dexamethasone injection(s) with or without migraine medications (a combination of nortriptyline and topiramate).
Results
A total of 47 patients received oral steroid and IT dexamethasone injection(s) only, and 46 patients received oral steroid and IT dexamethasone injection(s) as well as migraine lifestyle changes plus a combination of nortriptyline and topiramate. There were no significant differences in demographics and baseline audiometric data between the two groups. Both groups demonstrated improvements in pure tone average (PTA) and hearing thresholds at 250 Hz and 8000 Hz posttreatment. However, compared to steroid‐only group, the adjuvant migraine medications group had significantly greater improvements in hearing thresholds at the lower frequencies (250 Hz, 500 Hz, 1000 Hz). Patients in the latter cohort also had greater improvement in PTA (P = .01) and received fewer IT injections (P = .04) PTA improvement of ≥ 10 dB was observed in 36 patients (78%) in the adjuvant migraine medications group and 22 patients (46%) in the control group (P < .001).
Conclusion
In multimodal treatment of SSNHL, supplementing oral and IT steroid with migraine medications may result in greater improvements in lower frequency hearing thresholds and PTA. Furthermore, adjuvant migraine treatment can lead to decrease in number of IT injections, thus reducing procedure‐related risks and complications.
Level of Evidence
3 Laryngoscope, 131:E283–E288, 2021</description><identifier>ISSN: 0023-852X</identifier><identifier>EISSN: 1531-4995</identifier><identifier>DOI: 10.1002/lary.28618</identifier><identifier>PMID: 32243585</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Administration, Oral ; Adult ; Aged ; Dexamethasone - administration & dosage ; Drug Therapy, Combination ; Female ; Glucocorticoids - administration & dosage ; Hearing loss ; Hearing Loss, Sensorineural - drug therapy ; Hearing Loss, Sudden - drug therapy ; Humans ; Injection, Intratympanic ; intratympanic ; Male ; Middle Aged ; migraine ; Migraine Disorders - drug therapy ; Nortriptyline - administration & dosage ; Retrospective Studies ; sensorineural ; SSNHL ; Topiramate - administration & dosage</subject><ispartof>The Laryngoscope, 2021-01, Vol.131 (1), p.E283-E288</ispartof><rights>2020 The American Laryngological, Rhinological and Otological Society, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4208-d89b54e0cfc27b394bc987d32c2bedd7081d646dc3fa4a4e5c280ef4338e1ec53</citedby><cites>FETCH-LOGICAL-c4208-d89b54e0cfc27b394bc987d32c2bedd7081d646dc3fa4a4e5c280ef4338e1ec53</cites><orcidid>0000-0002-3585-698X ; 0000-0001-5905-0270 ; 0000-0003-2607-2582</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flary.28618$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flary.28618$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32243585$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abouzari, Mehdi</creatorcontrib><creatorcontrib>Goshtasbi, Khodayar</creatorcontrib><creatorcontrib>Chua, Janice T.</creatorcontrib><creatorcontrib>Tan, Donald</creatorcontrib><creatorcontrib>Sarna, Brooke</creatorcontrib><creatorcontrib>Saber, Tina</creatorcontrib><creatorcontrib>Lin, Harrison W.</creatorcontrib><creatorcontrib>Djalilian, Hamid R.</creatorcontrib><title>Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss</title><title>The Laryngoscope</title><addtitle>Laryngoscope</addtitle><description>Objectives/Hypothesis
To examine the hearing outcomes of patients with sudden sensorineural hearing loss (SSNHL) treated with oral and intratympanic (IT) steroid only or a combination of steroid and migraine treatment. Our hypothesis was that adjuvant migraine medications may improve outcomes in SSNHL.
Methods
A retrospective chart review at a tertiary otology center was conducted to identify patients with SSNHL who received oral steroid and IT dexamethasone injection(s) with or without migraine medications (a combination of nortriptyline and topiramate).
Results
A total of 47 patients received oral steroid and IT dexamethasone injection(s) only, and 46 patients received oral steroid and IT dexamethasone injection(s) as well as migraine lifestyle changes plus a combination of nortriptyline and topiramate. There were no significant differences in demographics and baseline audiometric data between the two groups. Both groups demonstrated improvements in pure tone average (PTA) and hearing thresholds at 250 Hz and 8000 Hz posttreatment. However, compared to steroid‐only group, the adjuvant migraine medications group had significantly greater improvements in hearing thresholds at the lower frequencies (250 Hz, 500 Hz, 1000 Hz). Patients in the latter cohort also had greater improvement in PTA (P = .01) and received fewer IT injections (P = .04) PTA improvement of ≥ 10 dB was observed in 36 patients (78%) in the adjuvant migraine medications group and 22 patients (46%) in the control group (P < .001).
Conclusion
In multimodal treatment of SSNHL, supplementing oral and IT steroid with migraine medications may result in greater improvements in lower frequency hearing thresholds and PTA. Furthermore, adjuvant migraine treatment can lead to decrease in number of IT injections, thus reducing procedure‐related risks and complications.
Level of Evidence
3 Laryngoscope, 131:E283–E288, 2021</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Dexamethasone - administration & dosage</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Hearing loss</subject><subject>Hearing Loss, Sensorineural - drug therapy</subject><subject>Hearing Loss, Sudden - drug therapy</subject><subject>Humans</subject><subject>Injection, Intratympanic</subject><subject>intratympanic</subject><subject>Male</subject><subject>Middle Aged</subject><subject>migraine</subject><subject>Migraine Disorders - drug therapy</subject><subject>Nortriptyline - administration & dosage</subject><subject>Retrospective Studies</subject><subject>sensorineural</subject><subject>SSNHL</subject><subject>Topiramate - administration & dosage</subject><issn>0023-852X</issn><issn>1531-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kVtLxDAQhYMoul5e_AGSRxGqubbpi7CIN1gRXAV9CmkyXSPdVpNW8d-bdVX0xacJzJczZ-YgtEvJISWEHTUmvB8ylVO1gkZUcpqJspSraJSaPFOS3W-gzRifCKEFl2QdbXDGBJdKjtB07J6GV9P2-MrPgvEt4Ctw3pred23EvsX9I-DbAKafQ6K6Gk8H56DFU2hjF9KHIZgGX4BJ7xmedDFuo7XaNBF2vuoWujs7vT25yCbX55cn40lmBSMqc6qspABia8uKipeisqUqHGeWVeBcQRR1ucid5bURRoC0TBGoBecKKFjJt9DxUvd5qObgbPKXrOjn4OfpIrozXv_ttP5Rz7pXrQilXOZJYP9LIHQvA8Rez3200DSmhW6ImnGVM1XIYoEeLFEb0oYB6p8xlOhFCnqRgv5MIcF7v439oN9nTwBdAm--gfd_pPRkfPOwFP0AGJ2U3g</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Abouzari, Mehdi</creator><creator>Goshtasbi, Khodayar</creator><creator>Chua, Janice T.</creator><creator>Tan, Donald</creator><creator>Sarna, Brooke</creator><creator>Saber, Tina</creator><creator>Lin, Harrison W.</creator><creator>Djalilian, Hamid R.</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3585-698X</orcidid><orcidid>https://orcid.org/0000-0001-5905-0270</orcidid><orcidid>https://orcid.org/0000-0003-2607-2582</orcidid></search><sort><creationdate>202101</creationdate><title>Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss</title><author>Abouzari, Mehdi ; Goshtasbi, Khodayar ; Chua, Janice T. ; Tan, Donald ; Sarna, Brooke ; Saber, Tina ; Lin, Harrison W. ; Djalilian, Hamid R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4208-d89b54e0cfc27b394bc987d32c2bedd7081d646dc3fa4a4e5c280ef4338e1ec53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Dexamethasone - administration & dosage</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Hearing loss</topic><topic>Hearing Loss, Sensorineural - drug therapy</topic><topic>Hearing Loss, Sudden - drug therapy</topic><topic>Humans</topic><topic>Injection, Intratympanic</topic><topic>intratympanic</topic><topic>Male</topic><topic>Middle Aged</topic><topic>migraine</topic><topic>Migraine Disorders - drug therapy</topic><topic>Nortriptyline - administration & dosage</topic><topic>Retrospective Studies</topic><topic>sensorineural</topic><topic>SSNHL</topic><topic>Topiramate - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abouzari, Mehdi</creatorcontrib><creatorcontrib>Goshtasbi, Khodayar</creatorcontrib><creatorcontrib>Chua, Janice T.</creatorcontrib><creatorcontrib>Tan, Donald</creatorcontrib><creatorcontrib>Sarna, Brooke</creatorcontrib><creatorcontrib>Saber, Tina</creatorcontrib><creatorcontrib>Lin, Harrison W.</creatorcontrib><creatorcontrib>Djalilian, Hamid R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Laryngoscope</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abouzari, Mehdi</au><au>Goshtasbi, Khodayar</au><au>Chua, Janice T.</au><au>Tan, Donald</au><au>Sarna, Brooke</au><au>Saber, Tina</au><au>Lin, Harrison W.</au><au>Djalilian, Hamid R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss</atitle><jtitle>The Laryngoscope</jtitle><addtitle>Laryngoscope</addtitle><date>2021-01</date><risdate>2021</risdate><volume>131</volume><issue>1</issue><spage>E283</spage><epage>E288</epage><pages>E283-E288</pages><issn>0023-852X</issn><eissn>1531-4995</eissn><abstract>Objectives/Hypothesis
To examine the hearing outcomes of patients with sudden sensorineural hearing loss (SSNHL) treated with oral and intratympanic (IT) steroid only or a combination of steroid and migraine treatment. Our hypothesis was that adjuvant migraine medications may improve outcomes in SSNHL.
Methods
A retrospective chart review at a tertiary otology center was conducted to identify patients with SSNHL who received oral steroid and IT dexamethasone injection(s) with or without migraine medications (a combination of nortriptyline and topiramate).
Results
A total of 47 patients received oral steroid and IT dexamethasone injection(s) only, and 46 patients received oral steroid and IT dexamethasone injection(s) as well as migraine lifestyle changes plus a combination of nortriptyline and topiramate. There were no significant differences in demographics and baseline audiometric data between the two groups. Both groups demonstrated improvements in pure tone average (PTA) and hearing thresholds at 250 Hz and 8000 Hz posttreatment. However, compared to steroid‐only group, the adjuvant migraine medications group had significantly greater improvements in hearing thresholds at the lower frequencies (250 Hz, 500 Hz, 1000 Hz). Patients in the latter cohort also had greater improvement in PTA (P = .01) and received fewer IT injections (P = .04) PTA improvement of ≥ 10 dB was observed in 36 patients (78%) in the adjuvant migraine medications group and 22 patients (46%) in the control group (P < .001).
Conclusion
In multimodal treatment of SSNHL, supplementing oral and IT steroid with migraine medications may result in greater improvements in lower frequency hearing thresholds and PTA. Furthermore, adjuvant migraine treatment can lead to decrease in number of IT injections, thus reducing procedure‐related risks and complications.
Level of Evidence
3 Laryngoscope, 131:E283–E288, 2021</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>32243585</pmid><doi>10.1002/lary.28618</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-3585-698X</orcidid><orcidid>https://orcid.org/0000-0001-5905-0270</orcidid><orcidid>https://orcid.org/0000-0003-2607-2582</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0023-852X |
| ispartof | The Laryngoscope, 2021-01, Vol.131 (1), p.E283-E288 |
| issn | 0023-852X 1531-4995 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8011356 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Administration, Oral Adult Aged Dexamethasone - administration & dosage Drug Therapy, Combination Female Glucocorticoids - administration & dosage Hearing loss Hearing Loss, Sensorineural - drug therapy Hearing Loss, Sudden - drug therapy Humans Injection, Intratympanic intratympanic Male Middle Aged migraine Migraine Disorders - drug therapy Nortriptyline - administration & dosage Retrospective Studies sensorineural SSNHL Topiramate - administration & dosage |
| title | Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A28%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20Migraine%20Medications%20in%20the%20Treatment%20of%20Sudden%20Sensorineural%20Hearing%20Loss&rft.jtitle=The%20Laryngoscope&rft.au=Abouzari,%20Mehdi&rft.date=2021-01&rft.volume=131&rft.issue=1&rft.spage=E283&rft.epage=E288&rft.pages=E283-E288&rft.issn=0023-852X&rft.eissn=1531-4995&rft_id=info:doi/10.1002/lary.28618&rft_dat=%3Cproquest_pubme%3E2386287576%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2386287576&rft_id=info:pmid/32243585&rfr_iscdi=true |